Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
D 67.65 -0.49% -0.33
ARWR closed down 0.49 percent on Friday, April 16, 2021, on 80 percent of normal volume.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical ARWR trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.49%
New Uptrend Bullish -0.49%
Bollinger Band Squeeze Range Contraction -0.49%
BB Squeeze Started Range Contraction -0.49%
Up 3 Days in a Row Strength -0.49%
Up 4 Days in a Row Strength -0.49%
Crossed Above 20 DMA Bullish 0.71%
Older End-of-Day Signals for ARWR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Arrowhead Research Corporation Description

Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Solid Tumors Organ Systems Genetics Molecular Biology Infection Melanoma Hepatitis B Gene Expression Library Obesity Peptides Hepatitis B Virus Companion Diagnostic RNA Rna Interference Biochemistry Chronic Hepatitis B Virus Molecular Genetics Apoptosis Chronic Hepatitis B Small Interfering Rna

Is ARWR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 92.6
52 Week Low 30.83
Average Volume 764,675
200-Day Moving Average 61.53
50-Day Moving Average 73.95
20-Day Moving Average 65.23
10-Day Moving Average 65.11
Average True Range 3.56
ADX 23.88
+DI 21.77
-DI 21.04
Chandelier Exit (Long, 3 ATRs ) 62.69
Chandelier Exit (Short, 3 ATRs ) 71.21
Upper Bollinger Band 69.92
Lower Bollinger Band 60.53
Percent B (%b) 0.76
BandWidth 14.40
MACD Line -1.74
MACD Signal Line -2.64
MACD Histogram 0.9051
Fundamentals Value
Market Cap 6.92 Billion
Num Shares 102 Million
EPS 0.09
Price-to-Earnings (P/E) Ratio 735.33
Price-to-Sales 73.24
Price-to-Book 14.24
PEG Ratio -1.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 71.01
Resistance 3 (R3) 71.24 70.36 70.45
Resistance 2 (R2) 70.36 69.50 70.24 70.26
Resistance 1 (R1) 69.00 68.97 68.56 68.77 70.08
Pivot Point 68.12 68.12 67.90 68.00 68.12
Support 1 (S1) 66.76 67.26 66.32 66.53 65.22
Support 2 (S2) 65.88 66.73 65.76 65.04
Support 3 (S3) 64.52 65.88 64.85
Support 4 (S4) 64.29